ARLENE SCORSONE: Open Payments
NPI 1295410710 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$415 in 26 payments from 12 companies in 2025. Trend: 2023 $23 · 2024 $323 · 2025 $415
Food & beverage: $415
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $163 |
| Madrigal Pharmaceuticals | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| La Jolla Pharmaceutical Company | 1 | $28 |
| ORPHALAN INC | 1 | $24 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
| Eton Pharmaceuticals, Inc. | 1 | $22 |
| Kerecis Limited | 1 | $22 |
| Novo Nordisk Inc | 1 | $18 |
| Celltrion USA Inc. | 1 | $18 |
Products named: XIFAXAN, REZDIFFRA, LIVTENCITY, GIAPREZA, CUVRIOR, OCALIVA, GALZIN, Kerecis SurgiClose.
Industry payments across TX — which companies pay providers there.
